Literature DB >> 20689081

Lack of association between pretreatment neurology consultation and subsequent protocol deviation in tissue plasminogen activator-treated patients with stroke.

William J Meurer1, Angela F Caveney, Alex Lo, Lingling Zhang, Shirley M Frederiksen, Annette M Sandretto, Robert Silbergleit, Phillip A Scott.   

Abstract

BACKGROUND AND
PURPOSE: We evaluated the hypothesis that consultation with neurology would be associated with fewer protocol deviations in tissue plasminogen activator-treated patients with stroke.
METHODS: A retrospective analysis of consecutive tissue plasminogen activator-treated patients with acute patients was performed. Using chi(2) tests, the proportion of patients with a protocol deviation was calculated and compared between those with evidence of a neurology consultation and those without. Logistic regression was then used to determine the OR for protocol deviation at the same time as controlling for clinical presentation covariates.
RESULTS: Two hundred seventy-three subjects were included. Protocol deviation rates did not significantly differ between those with (44%) and those without (41%) a consultation. The adjusted OR for deviation comparing any consultation versus nonconsultation was 1.25 (95% CI: 0.58 to 2.68). There was no statistically significant difference between symptomatic intracranial hemorrhage and in-hospital mortality rates between the groups. The proportion of patients with pretreatment deviations not related to timing was low in both the consultation (9.7%) and nonconsultation groups (8.1%).
CONCLUSIONS: Neurological consultation was not found to be associated with decreased protocol deviations in this cohort, although the high proportion of deviations with and without consultation suggests that quality improvement is needed. Most observed pretreatment deviations were attributable to timing. As acute stroke care becomes more efficient and additional methods in reducing door-to-treatment times are sought, models in which emergency physicians direct the initial phase of treatment may merit further consideration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689081      PMCID: PMC3530417          DOI: 10.1161/STROKEAHA.110.588491

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

1.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

2.  Cuyahoga County Operation Stroke speed of emergency department evaluation and compliance with National Institutes of Neurological Disorders and Stroke time targets.

Authors:  Irene L Katzan; Thomas M Graber; Anthony J Furlan; Sophia Sundararajan; Cathy A Sila; Gary Houser; Dennis M Landis
Journal:  Stroke       Date:  2003-03-06       Impact factor: 7.914

3.  Time is brain--quantified.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

4.  Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.

Authors:  A M Lopez-Yunez; A Bruno; L S Williams; E Yilmaz; C Zurrú; J Biller
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Use of thrombolysis in acute ischemic stroke: analysis of the Nationwide Inpatient Sample 1999 to 2004.

Authors:  H Christian Schumacher; Brian T Bateman; Bernadette Boden-Albala; Mitchell F Berman; J P Mohr; Ralph L Sacco; John Pile-Spellman
Journal:  Ann Emerg Med       Date:  2007-05-03       Impact factor: 5.721

7.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

8.  Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.

Authors:  Glenn D Graham
Journal:  Stroke       Date:  2003-11-06       Impact factor: 7.914

9.  Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

Authors:  Gregory J Del Zoppo; Jeffrey L Saver; Edward C Jauch; Harold P Adams
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

10.  Chart reviews in emergency medicine research: Where are the methods?

Authors:  E H Gilbert; S R Lowenstein; J Koziol-McLain; D C Barta; J Steiner
Journal:  Ann Emerg Med       Date:  1996-03       Impact factor: 5.721

View more
  2 in total

1.  Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.

Authors:  Lee S Chung; Aleksander Tkach; Erin M Lingenfelter; Sarah B Dehoney; Jeannie Rollo; Adam de Havenon; L Dana DeWitt; Matthew R Grantz; Haimei Wang; Jana J Wold; Peter M Hannon; Natalie R Weathered; Jennifer J Majersik
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-12-11       Impact factor: 2.136

2.  Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Authors:  Eric E Adelman; Phillip A Scott; Lesli E Skolarus; Allison K Fox; Shirley M Frederiksen; William J Meurer
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-26       Impact factor: 2.136

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.